PMID- 29957442
OWN - NLM
STAT- MEDLINE
DCOM- 20190503
LR  - 20190503
IS  - 1873-3360 (Electronic)
IS  - 0306-4530 (Linking)
VI  - 96
DP  - 2018 Oct
TI  - Increased plasma Interleukin-1beta level is associated with memory deficits in type 
      2 diabetic patients with mild cognitive impairment.
PG  - 148-154
LID - S0306-4530(18)30157-4 [pii]
LID - 10.1016/j.psyneuen.2018.06.014 [doi]
AB  - Type 2 diabetes mellitus (T2DM) and mild cognitive impairment (MCI) are both 
      chronic inflammatory diseases. We aimed to investigate the association of plasma 
      Interleukin-1beta (IL-1beta) levels with the risk of MCI in T2DM patients. We divided 
      recruited T2DM patients into two groups, MCI group and healthy-cognition 
      controls, according to Montreal Cognitive Assessment (MoCA) scores. Demographic 
      characteristics, clinical parameters and neuropsychological tests were examined. 
      We recruited 202 T2DM patients in this study, including 94 MCI and 108 
      healthy-cognition controls. T2DM patients with MCI exhibited increased plasma 
      IL-1beta and decreased amyloid-beta 42 (Abeta42) levels compared to the controls (all 
      p < 0.05). After adjusting fasting blood glucose (FBG), glycosylated hemoglobin 
      (HbA1c), homeostasis model assessment of insulin resistance (HOMA-IR) and Abeta42, 
      plasma IL-1beta levels were negatively correlated with MoCA and AVLT delayed recall 
      scores, which represented memory function. Multivariable logistic regression 
      model showed that high plasma IL-1beta level and low plasma Abeta42 level were 
      correlated with increased risk for MCI in T2DM patients. Increased plasma IL-1beta 
      level was significantly associated with MCI in T2DM patients, especially memory 
      deficits. Our findings will provide additional insights into the inflammation 
      pathogenesis of cognitive impairments in T2DM.
CI  - Copyright (c) 2018 Elsevier Ltd. All rights reserved.
FAU - Tian, Sai
AU  - Tian S
AD  - Department of Endocrinology, Affiliated Zhongda Hospital of Southeast University, 
      Nanjing, PR China; Medical School of Southeast University, Nanjing, PR China.
FAU - Huang, Rong
AU  - Huang R
AD  - Department of Endocrinology, Affiliated Zhongda Hospital of Southeast University, 
      Nanjing, PR China.
FAU - Han, Jing
AU  - Han J
AD  - Department of Endocrinology, Affiliated Zhongda Hospital of Southeast University, 
      Nanjing, PR China.
FAU - Cai, Rongrong
AU  - Cai R
AD  - Department of Endocrinology, Affiliated Zhongda Hospital of Southeast University, 
      Nanjing, PR China.
FAU - Guo, Dan
AU  - Guo D
AD  - Department of Endocrinology, Affiliated Zhongda Hospital of Southeast University, 
      Nanjing, PR China.
FAU - Lin, Hongyan
AU  - Lin H
AD  - Department of Endocrinology, Affiliated Zhongda Hospital of Southeast University, 
      Nanjing, PR China.
FAU - Wang, Jiaqi
AU  - Wang J
AD  - Department of Endocrinology, Affiliated Zhongda Hospital of Southeast University, 
      Nanjing, PR China.
FAU - Wang, Shaohua
AU  - Wang S
AD  - Department of Endocrinology, Affiliated Zhongda Hospital of Southeast University, 
      Nanjing, PR China. Electronic address: gyjwsh@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180622
PL  - England
TA  - Psychoneuroendocrinology
JT  - Psychoneuroendocrinology
JID - 7612148
RN  - 0 (Amyloid beta-Peptides)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Peptide Fragments)
RN  - 0 (amyloid beta-protein (1-42))
SB  - IM
MH  - Aged
MH  - Amyloid beta-Peptides/analysis/blood
MH  - Case-Control Studies
MH  - Cognition
MH  - Cognitive Dysfunction/*metabolism
MH  - Diabetes Mellitus, Type 2/complications/metabolism
MH  - Female
MH  - Humans
MH  - Interleukin-1beta/*analysis/blood
MH  - Male
MH  - Memory Disorders/*metabolism/physiopathology
MH  - Middle Aged
MH  - Neuropsychological Tests
MH  - Peptide Fragments/analysis/blood
MH  - Risk Factors
OTO - NOTNLM
OT  - Amyloid-beta
OT  - Interleukin-1beta
OT  - Mild cognitive impairment
OT  - Type 2 diabetes mellitus
EDAT- 2018/06/30 06:00
MHDA- 2019/05/06 06:00
CRDT- 2018/06/30 06:00
PHST- 2018/02/23 00:00 [received]
PHST- 2018/05/15 00:00 [revised]
PHST- 2018/06/16 00:00 [accepted]
PHST- 2018/06/30 06:00 [pubmed]
PHST- 2019/05/06 06:00 [medline]
PHST- 2018/06/30 06:00 [entrez]
AID - S0306-4530(18)30157-4 [pii]
AID - 10.1016/j.psyneuen.2018.06.014 [doi]
PST - ppublish
SO  - Psychoneuroendocrinology. 2018 Oct;96:148-154. doi: 
      10.1016/j.psyneuen.2018.06.014. Epub 2018 Jun 22.